June 21, 2018
Shire Announces FDA Approval for Label Expansion of CINRYZE® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients

May 16, 2018
KalVista Pharmaceuticals Recognizes HAE Day

April 9, 2018
HAEA comments on ICER HAE therapy assessment

February 25, 2018
FDA Accepts Shire’s Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients

February 15, 2018
Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use

January 24, 2018
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site

January 22, 2018
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases

January 8, 2018
A Big Pharma-funded charity that helps patients pay for drugs just sued the government

January 5, 2018
KalVista Pharmaceuticals Commences Two Clinical Trials

September 29, 2017
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema

September 14, 2017
KalVista Pharmaceuticals Reports Fiscal First Quarter Results

September 11, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

September 11, 2017
Pharming announces conclusion of FDA End of Phase 2 interactions on RUCONEST® for Prophylaxis of HAE

September 5, 2017
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE

July 26, 2017
Pharming announces publication of RUCONEST® prophylactic data in The Lancet

July 23, 2017
FDA Approves HAEGARDA® King Of Prussia, PA

June 22, 2017
FDA Approves First Subcutaneous C1 Esterase Inhibitor To Treat Rare Genetic Disease

May 24, 2017
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

May 24, 2017
Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

April 13, 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks

March 23, 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients